MARKET

CDTX

CDTX

Cidara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.390
-0.010
-0.42%
Closed 16:00 11/15 EST
OPEN
2.430
PREV CLOSE
2.400
HIGH
2.539
LOW
2.350
VOLUME
349.37K
TURNOVER
--
52 WEEK HIGH
3.840
52 WEEK LOW
1.223
MARKET CAP
78.97M
P/E (TTM)
-1.1831
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CDTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CDTX News

  • Cidara Therapeutics EPS beats by $0.18, beats on revenue
  • seekingalpha.11/08 08:52
  • Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results
  • GlobeNewswire.11/08 02:17
  • Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs
  • GlobeNewswire.11/05 13:00
  • Weekly CFO Buys Highlight
  • GuruFocus.com.10/07 01:22

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About CDTX

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.
More

Webull offers Cidara Therapeutics Inc (CDTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.